Triple-negative breast cancer (TNBC), which accounts for 10–20% of all breast cancers (BCs) worldwide [1], is characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.